DNA methylation state of the galectin‑3 gene represents a potential new marker of thyroid malignancy

  • Authors:
    • Simona Keller
    • Tiziana Angrisano
    • Ermanno Florio
    • Raffaela Pero
    • Miriam Decaussin‑Petrucci
    • Giancarlo Troncone
    • Mario Capasso
    • Francesca Lembo
    • Alfredo Fusco
    • Lorenzo Chiariotti
  • View Affiliations

  • Published online on: April 18, 2013     https://doi.org/10.3892/ol.2013.1312
  • Pages: 86-90
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In order to supplement the cytopathological assessment of thyroid tumors, there is a need for new markers to correctly diagnose malignant thyroid lesions and avoid unnecessary and potentially harmful therapies for patients. The immunohistochemical expression of galectin-3 is currently considered to be the most accurate stand-alone marker for thyroid cancer diagnosis. The aim of this study was to establish whether the methylation state of the galectin-3 gene is a candidate molecular marker for thyroid malignancy. Thyroid specimens from 50 patients were analyzed, including 5 normal thyroid, 3 goiters, 39 papillary and 3 anaplastic thyroid carcinoma cases. High-resolution methylation analyses was performed to investigate the methylation state of a large genomic region (from -89 to +408) encompassing the galectin-3 transcriptional start site. Within this region, 5 CpG sites (nucleotide positions +134, +137, +142, +147 and +156) were observed to be differentially methylated among the samples and were further analyzed by the quantitative pyrosequencing technique. The hypomethylation of the +134, +137, +142, +147 and +156 CpG sites was observed to be markedly associated with cancer. Although the methylation degree of each single site was highly variable in non-neoplastic tissues, the average methylation state of the 5 CpG sites clearly distinguished cancer from the non-neoplastic thyroid tissues.
View Figures
View References

Related Articles

Journal Cover

July 2013
Volume 6 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Keller S, Angrisano T, Florio E, Pero R, Decaussin‑Petrucci M, Troncone G, Capasso M, Lembo F, Fusco A, Chiariotti L, Chiariotti L, et al: DNA methylation state of the galectin‑3 gene represents a potential new marker of thyroid malignancy. Oncol Lett 6: 86-90, 2013.
APA
Keller, S., Angrisano, T., Florio, E., Pero, R., Decaussin‑Petrucci, M., Troncone, G. ... Chiariotti, L. (2013). DNA methylation state of the galectin‑3 gene represents a potential new marker of thyroid malignancy. Oncology Letters, 6, 86-90. https://doi.org/10.3892/ol.2013.1312
MLA
Keller, S., Angrisano, T., Florio, E., Pero, R., Decaussin‑Petrucci, M., Troncone, G., Capasso, M., Lembo, F., Fusco, A., Chiariotti, L."DNA methylation state of the galectin‑3 gene represents a potential new marker of thyroid malignancy". Oncology Letters 6.1 (2013): 86-90.
Chicago
Keller, S., Angrisano, T., Florio, E., Pero, R., Decaussin‑Petrucci, M., Troncone, G., Capasso, M., Lembo, F., Fusco, A., Chiariotti, L."DNA methylation state of the galectin‑3 gene represents a potential new marker of thyroid malignancy". Oncology Letters 6, no. 1 (2013): 86-90. https://doi.org/10.3892/ol.2013.1312